DOCOMO to Exhibit at MWC Barcelona 2025, World's Largest Connectivity Exhibition
24.1.2025 06:01:00 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will exhibit at MWC Barcelona 2025, the world's largest connectivity exhibition, in Barcelona, Spain from March 3 to 6. DOCOMO and its parent NTT Group will showcase technologies and initiatives focused on the core themes of non-terrestrial networks (NTN) and aerospace, open radio access networks (Open RAN), and entertainment, aiming to promote international standardization and new business focused on next-generation communication technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123714093/en/
NTT DOCOMO Booth at MWC Barcelona 2025 (Graphic: Business Wire)
DOCOMO is developing cutting-edge technologies and businesses under its brand slogan “Bridging Worlds for Wonder & Happiness.”
In the NTN and aerospace field, DOCOMO will highlight its latest initiatives under the NTT Group’s “NTT C89” space-business strategy, such as mobile-connectivity services using unmanned vehicles, or high-altitude platform stations (HAPS), that fly in the stratosphere for days or months, using relays to provide mobile connectivity in mountainous and remote areas, including at sea and in the sky.
For Open RAN, DOCOMO will showcase collaborations with global telecom operators, and also Open RAN services that leverage the strengths of various global partners, offered by OREX SAI, INC., a joint venture with NEC.
In the entertainment field, DOCOMO will display MiRZA® XR glasses by NTT QONOQ Devices, Inc., designed for diverse use cases including enterprise solutions, including a touch-and-try demonstration of the NTT XR Real Support solution for remote work enabled by XR glasses. A commercial prototype of AR glasses, which are scheduled to be released from this summer onwards, will also be on display (final specifications may vary).
Additionally, DOCOMO will showcase FEEL TECH®,an innovative technology that transforms how sensory information are shared, tailoring to the other person’s unique perception. Through a demonstration that conveys the emotions and sensations of characters alongside visuals and sound, visitors will have the opportunity to experience DOCOMO’s vision for the future of entertainment.
DOCOMO will also showcase the Virtual EXPO of Expo 2025 primarily developed by NTT QONOQ, INC. aiming for a service launch in April. This virtual site allows visitors to experience the NTT Pavilion using various devices.
DOCOMO’s booth at MWC Barcelona 2025 will be located at Stand 4E50 in Hall 4. During the exhibition, Mr. Sadayuki Abeta, Chief Open RAN Strategist at NTT DOCOMO and Chief Technology Officer at OREX SAI, will give a presentation on his company’s latest initiatives, case histories and future plans at the MWC Broadcast Stage 2025 in Hall 4 on Tuesday, March 4 from 16:15 to 16:45 (please see MWC Barcelona 2025 website to confirm final content and schedule).
About MWC Barcelona 2025
https://www.mwcbarcelona.com/
When:
March 3 to 6
08:30 to 19:00 (16:00 on last day)
Where:
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
NTT C89 is pending trademark registration.
MiRZA® is a registered trademark of NTT QONOQ Devices, Inc. in Japan.
FEEL TECH® is a registered trademark of NTT DOCOMO, INC. in Japan
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 89 million subscribers, is one of the global leaders in 3G, 4G and 5G mobile network technologies.
Under the slogan "Bridging Worlds for Wonder & Happiness," DOCOMO is actively collaborating with global partners to expand its business scope from mobile services to comprehensive solutions, aiming to deliver unsurpassed value and drive innovation in technology and communications, ultimately to support positive change and advancement in global society.
https://www.docomo.ne.jp/english/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123714093/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 14:00:00 CET | Press release
The combination connects AI-driven financial and operational planning, analytics and execution across Microsoft Excel and Power BI, removing decision latency for Microsoft-centric enterprises. Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap wid
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 14:00:00 CET | Press release
• 45% of C-level executives plan to establish a U.S. legal entity within the next 12 months; a further 27% say they will consider entry within two to three years • 65% cite supply chain or manufacturing efficiency as the primary driver for U.S. expansion • 88% identify federal and state tax reporting as the most burdensome area of U.S. compliance Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expa
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release
COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom